Ironwood Pharmaceuticals, Inc. (IRWD)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Ms. Julie H. McHugh | Executive Chairman of the Board | 95k | -- | 1964 |
| Mr. Thomas A. McCourt | CEO & Director | 1.42M | -- | 1957 |
| Mr. Sravan Kumar Emany | Senior VP, Principal Financial Officer & CFO | 712.36k | -- | 1979 |
| Mr. John Minardo | Senior VP, Chief Legal Officer & Secretary | 675.88k | -- | 1977 |
| Dr. Michael Shetzline M.D., Ph.D. | Chief Medical Officer, Senior VP and Head of Research & Drug Development | 837.74k | -- | 1960 |
| Mr. Ronald Silver | Corporate Controller & Principal Accounting Officer | -- | -- | 1983 |
| Mr. Marcel Moulaison | Vice President of Technical Operations | -- | -- | -- |
| Greg Martini | Vice President of Strategic Finance & Investor Relations | -- | -- | -- |
| Ms. Beth Calitri | Head of Corporate Communications & Media Relations | -- | -- | -- |
| Mr. Mike Nanfito | Vice President of Sales & Sales Excellence | -- | -- | -- |
Ironwood Pharmaceuticals, Inc.
- Sector:
- Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
- Full Time Employees:
- 267
Description
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.
Corporate Governance
Recent Events
- Feb 16, 202410-K: Periodic Financial ReportsSee Full Filing
- Feb 15, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Jan 25, 2024SC 13G/A: Tender Offer/Acquisition ReportsSee Full Filing
- Jan 22, 2024SC 13G/A: Tender Offer/Acquisition ReportsSee Full Filing
- Jan 08, 20248-K: Corporate Changes & Voting MattersSee Full Filing